Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months

뉴스 본문을 불러오고 있어요.

Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months | 웨이프 WAPE

Corvus Pharmaceuticals Says Phase 1/1b Soquelitinib T Cell Lymphoma Data Published In Blood Showed Objective Responses In 9 Of 24 Patients, Median Overall Survival Of 28.1 Months

기사 요약

관련 종목

댓글 —